Zoledronic Acid Regulates Osteoclasts via miR ‐483‐5p in the BRONJ
Oral Diseases · 2025
DOI: 10.1111/odi.15233 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, 2025. Verfasst von Zhiyong Guo und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases, West China Hospital of…. Hauptthemen laut MEDLINE: Zoledronic Acid, MicroRNAs, Osteoclasts, Bisphosphonate-Associated Osteonecrosis of the Jaw. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Exploration and R&D Project from West China hospital of Stomatology, Sichuan University, Postdoctoral Fellowship Program of CPSF, Scientific Research Foundation of the Science and Technology Department of Sichuan Province, China.
Abstract (Originalsprache)
Objectives
Bisphosphonate‐related osteonecrosis of the jaw (BRONJ) is a severe complication of bisphosphonate therapy, with unclear mechanisms. This study investigates the regulatory impact of zoledronic acid (ZOL) on osteoclasts and microRNA (miRNA) expression. Materials and Methods Raw264.7 cells and bone marrow‐derived macrophages (BMMs) were used to assess ZOL's effects on proliferation and apoptosis. miRNA array analysis was performed during osteoclastogenesis with ZOL treatment. The role of miR‐483‐5p was examined using miR‐mimics and miR‐inhibitors. A rat BRONJ model was established for in vivo validation.
Results
A concentration of 2 μM ZOL, which did not affect cell proliferation or apoptosis, was used in subsequent experiments. ZOL altered the expression of 64 miRNAs (39 upregulated, 25 downregulated). miR‐483‐5p mimics alleviated ZOL‐induced inhibition of osteoclastogenesis, actin ring formation, bone resorption, and differentiation marker expression, whereas inhibitors enhanced these effects. In vivo, Ago‐miR‐483‐5p promoted wound healing in the BRONJ model, while Antago‐miR‐483‐5p impaired it.
Conclusions
ZOL modulates osteoclast function in BRONJ through miR‐483‐5p inhibition. miR‐483‐5p may serve as a novel therapeutic target for BRONJ treatment, providing new insights into managing this complication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.
- Department of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.
- Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.
Förderung
- Exploration and R&D Project from West China hospital of Stomatology, Sichuan University
- Postdoctoral Fellowship Program of CPSF
- Scientific Research Foundation of the Science and Technology Department of Sichuan Province, China
Zitieren
APA
Guo, Z., Yang, J., Li, C., Tang, X., & Liu, J. (2025). Zoledronic Acid Regulates Osteoclasts via miR ‐483‐5p in the BRONJ. Oral Diseases. https://doi.org/10.1111/odi.15233
Vancouver
Guo Z, Yang J, Li C, Tang X, Liu J. Zoledronic Acid Regulates Osteoclasts via miR ‐483‐5p in the BRONJ. Oral Diseases. 2025. doi:10.1111/odi.15233
BibTeX
@article{Guo2025,
author = {Guo, Zhiyong and Yang, Jiajin and Li, Chunjie and Tang, Xiufa and Liu, Jiyuan},
title = {Zoledronic Acid Regulates Osteoclasts via miR ‐483‐5p in the BRONJ},
journal = {Oral Diseases},
year = {2025},
doi = {10.1111/odi.15233}
}
EUVIMED